Private company

NEXIEN BIOPHARMA, INC.

NEXIEN BIOPHARMA, INC. is an American pharmaceutical preparations company based in Glendale.2

Last updated Oct 20, 2026.

Overview

-$239.1KNet income, fiscal 20243
  • IndustryPharmaceutical Preparations2
  • HeadquartersGlendale, United States2
  • Incorporated inDE4
  • Business address4340 E Kentucky Ave, Suite 206, Glendale, Co 802464
  • Filer categoryNon-accelerated filer, Smaller reporting company4
  • Legal formCorporation2
  • LEI549300NXFNUW5RBMGY842
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O Harvard Business Services, Inc., 19958 Lewes, United States2
  • Registered withDivision of Corporations, Department of State, 45095752

See how the biggest companies compare on our leaderboards

“us” and “our” are to Nexien BioPharma, Inc., a Delaware corporation, formerly Intiva BioPharma Inc.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2017

-3.8%Return on equity6

Financial statements

Fiscal year2017
Revenue$07
Research and development
Operating expenses
Operating income
Interest$5.8K7
Net income-$21.7K7
Earnings per share
Earnings per share (diluted)
Shares (weighted, basic)
Shares (weighted, diluted)

Compare NEXIEN BIOPHARMA, INC. with another company

What it owns

What NEXIEN BIOPHARMA, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$4.2K3 Jun 30, 2024$35.1K3 Jun 30, 2023−88.1%

Properties, in its own words

Our principal office is located at 4340 East Kentucky Avenue, Suite 206, Glendale, Colorado 80246. Our telephone number is (303) 495-7583. Our offices consist of approximately 300 square feet of executive offices, and we believe that these facilities will be sufficient for the next twelve months.

Item 2 of the 10-K filed Oct 22, 2024.5

Leadership

Who has led NEXIEN BIOPHARMA, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ivo Heiden2016
  2. Jeffrey Friedland2017–2018
  3. Alain D. Bankier2018
  4. Alexander Michael Wasyl2018
  5. Richard S. Greenberg2020–2024

Chair

  1. Ivo Heiden2016
  2. Richard S. Greenberg2017–2018
  3. Alain D. Bankier2018

Chief financial officer

  1. Evan L. Wasoff2017–2024

Chief operating officer

  1. Robert I. Goldfarb2017–2023
20202025
Board members and other officers (11)

Former names

  • Intiva BioPharma Inc.Nov 29, 2017 to Sep 12, 20184
  • Kinder Holding Corp.Nov 14, 2014 to Nov 6, 20174

Timeline

  1. Jan 21, 20228-K Entered a material agreement; New debt or obligation; Unregistered sale of shares29
  2. Aug 14, 2020New chief executive Richard S. Greenberg becomes CEO11
  3. Nov 1, 2018New chief executive Alexander Michael Wasyl becomes CEO13
  4. May 23, 2018New chief executive Alain D. Bankier becomes CEO12
  5. Oct 17, 2017New chief executive Jeffrey Friedland becomes CEO14
  6. Sep 6, 2016New chief executive Ivo Heiden becomes CEO15

Filings

44 filings to the SEC since October 2021: 4 annual reports, 12 quarterly reports, 1 major events, 22 insider forms, 5 other. The latest 20:

  1. Sep 19, 202515-12G EDGAR
  2. May 14, 202510-Q EDGAR
  3. Feb 14, 202510-Q EDGAR
  4. Nov 18, 202410-Q EDGAR
  5. Nov 14, 2024NT 10-Q EDGAR
  6. Oct 22, 202410-K EDGAR
  7. Sep 30, 2024NT 10-K EDGAR
  8. May 28, 20244 PRIMARY DOCUMENT EDGAR
  9. May 28, 20244 PRIMARY DOCUMENT EDGAR
  10. May 15, 202410-Q EDGAR
  11. Feb 20, 202410-Q EDGAR
  12. Feb 14, 2024NT 10-Q EDGAR
  13. Nov 14, 202310-Q EDGAR
  14. Nov 2, 20234 PRIMARY DOCUMENT EDGAR
  15. Nov 2, 20234 PRIMARY DOCUMENT EDGAR
  16. Sep 28, 202310-K EDGAR
  17. Aug 3, 20234 PRIMARY DOCUMENT EDGAR
  18. Jul 31, 20234 PRIMARY DOCUMENT EDGAR
  19. Jul 31, 20234 PRIMARY DOCUMENT EDGAR
  20. May 17, 202310-Q EDGAR

The 44 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

SEC filer profile

How NEXIEN BIOPHARMA, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNEXIEN BIOPHARMA, INC.1
  • CIK0001625288
  • Employer ID (EIN)26-20493765
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company5
  • Incorporated inDelaware5
  • Fiscal year endsJune 301
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address4340 E Kentucky Ave, Suite 206, Glendale, CO 802461
  • Phone30349575831
  • Shares outstanding70,772,196 as of May 13, 20259
  • Public float$687.0K as of Dec 31, 20235
  • AuditorM&K CPAS, PLLC, The Woodlands, TX PCAOB ID 2738; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceNov 14, 20141
  • Filings201 in all: 4 (62), 8-K (33), 10-Q (32), 3 (14), 10-K (10), UPLOAD (10), CORRESP (7), 10-12G/A (3)1
    All 26 form types

    4/A (3), DRSLTR (3), NT 10-Q (3), D (2), DEF 14C (2), DRS/A (2), NT 10-K (2), S-1/A (2), SC 13D/A (2), 10-12G (1), 15-12G (1), 3/A (1), DRS (1), EFFECT (1), PRE 14C (1), S-1 (1), SC 13D (1), SC 13G (1)

  • Latest filingsAnnual report (10-K) Oct 22, 2024
    Quarterly report (10-Q) May 14, 2025
    Latest 8-K (8-K) Jan 21, 2022

Risk factors and legal proceedings

The risks NEXIEN BIOPHARMA, INC. names in Item 1A of its 10-K filed Oct 22, 2024: 55 risks under these headings, as written.5

  • Risks Related to Our Financial Position and Capital Requirements
  • Our independent registered public accounting firm has expressed substantial doubt as to our ability to continue as a going concern.
  • The Company has negative cash flow for the financial year ended June 30, 2024.
  • We face many of the risks and difficulties frequently encountered by relatively new companies with respect to our operations.
  • We currently have no revenues and may never become profitable.
  • We will require additional capital to fund our operations and if we fail to obtain necessary financing, we will not be able to complete any of our drug development projects
  • Raising additional capital may cause dilution to our existing stockholders and restrict our operations.
  • The Company’s officers and directors may be engaged in a range of business activities resulting in potential conflicts of interest.
  • The Company is subject to uncertainty regarding legal and regulatory status and changes.
  • Risks Relating to Our Drug Development Projects
  • Our future success will largely depend on the success of our drug candidates, which development will require significant capital resources and years of clinical development effort.
  • Our drug development projects, if approved, may be unable to achieve the expected market acceptance and, consequently, limit our ability to generate revenue.
The other 45 risks
  • Results of preclinical studies and earlier clinical trials are not necessarily predictive indicators of future results.
  • The regulatory approval processes with the FDA, the EMA and other comparable foreign regulatory authorities is lengthy and inherently unpredictable.
  • We may apply for orphan drug status granted by the FDA for some of our drug candidates for the treatment of rare diseases.
  • Our drug candidates may become subject to controlled substance laws and regulations in the U.S.
  • At present we have no guaranteed or reliable source of synthetic cannabinoids at an economically feasible price – even though we intend to focus on the utilization of synthetic cannabinoids
  • Laws and regulations affecting therapeutic uses of cannabis are constantly evolving.
  • Our research activities in the cannabinoid drug industry may make it difficult to obtain insurance coverage.
  • We face a potentially highly competitive market.
  • Our failure to comply with existing and potential future laws and regulations relating to drug development could harm our plan of operations.
  • Changes in legislation or regulation in the health care systems in the United States and foreign jurisdictions may affect us.
  • We will need to increase the size of our organization and may experience difficulties in managing growth.
  • We may not be able to successfully expand our business through acquisitions.
  • Risks Related to Collaboration with Third Parties and Intellectual Property Rights
  • We will depend on third parties to conduct our research activities.
  • If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our drug candidates, our competitive position could be harmed.
  • Costly litigation may be necessary to protect our intellectual property rights and we may be subject to claims alleging the violation of the intellectual property rights of others.
  • We will rely on confidentiality agreements that could be breached and may be difficult to enforce, which could result in third parties using our intellectual property to compete against us.
  • Intellectual property rights may not necessarily address all potential threats to our competitive advantage.
  • Risks Related to Our Common Stock
  • There can be no assurance of a liquid public trading market for our Common Stock or whether investors will be able to readily be able to sell their shares of Common Stock.
  • In the event an active trading market develops for our Common Stock, the market price may, from time-to-time, be volatile.
  • A large number of additional shares will be available for resale into the public market pursuant to Rule 144, which may cause the market price of our Common Stock to decline significantly.
  • You may experience dilution of your ownership interest because of the potential of future issuance of additional shares of our Common Stock or our preferred stock.
  • We may never pay any dividends to our stockholders.
  • Insiders will continue to have substantial control over us and will be able to influence corporate matters.
  • Our Common Stock is thinly traded, so stockholders may be unable to sell at or near ask prices, or at all, if they need to sell shares to raise money or otherwise desire to liquidate their shares.
  • Anti-takeover provisions of the Delaware General Corporation Law may discourage or prevent a change of control, even if an acquisition would be beneficial to our stockholders, which could reduce our stock price.
  • State Blue Sky registration and potential limitations on resale of our Common Stock.
  • Our Common Stock is considered a Penny Stock, which may be subject to restrictions on marketability, so you may not be able to sell your shares.
  • The control deficiencies in our Internal control over financial reporting may until remedied cause errors in our financial statements or cause our filings with the SEC to not be timely.
  • Reporting requirements under the Exchange Act and compliance with the Sarbanes-Oxley Act of 2002 (SOX), including establishing and maintaining acceptable internal controls over financial reporting, are costly and may increase substantially.
  • Our by-laws provide for indemnification of our directors and the purchase of D&O insurance at our expense and limit their potential or actual liability which may result in a significant cost to us and damage the interests of our stockholders.
  • Financial Industry Regulatory Authority, Inc. (“FINRA”) sales practice requirements may limit a stockholder’s ability to buy and sell our Common Stock.
  • If we fail to maintain effective internal controls over financial reporting, the price of our Common Stock may be adversely affected.
  • We are required to comply with certain provisions of Section 404 of SOX and if we fail to comply in a timely manner, our business could be harmed, and our stock price could decline.
  • Our share price could be volatile, and our trading volume may fluctuate substantially.
  • Our annual and quarterly results may fluctuate greatly, which may cause substantial fluctuations in our Common Stock price.
  • Risks Related to the Regulation of Cannabis in the United States
  • While cannabis is legal in many U.S. state jurisdictions, it continues to be a controlled substance under the United States CSA.
  • The approach to the enforcement of cannabis laws may be subject to change or may not proceed as previously outlined.
  • Regulatory scrutiny of the Company’s industry may negatively impact its ability to raise additional capital.
  • State and local laws and regulations may heavily regulate brands and forms of cannabis products and there is no guarantee that the Company’s proposed products and brands will be approved for sale and distribution in any state.
  • We may have difficulties accessing the services of banks in the United States due to the nature of our business.
  • Due to the classification of cannabis as a Schedule I controlled substance under the CSA, banks and other financial institutions which service the cannabis industry are at risk of violating certain financial laws, including anti-money laundering statutes.
  • Any re-classification of cannabis or changes in U.S. controlled substance laws and regulations may affect the Company’s business.
  • CBD is classified as Schedule I controlled substance. The DEA recently published a final rule in the Federal Register creating a new drug code for “marijuana extracts”.
  • U.S. federal trademark and patent protection may not be available for the intellectual property of the Company due to the current classification of cannabis as a Schedule I controlled substance.
  • The Company’s contracts may not be legally enforceable in the United States.

Legal proceedings

There are no pending legal proceedings to which the Company is a party, and the Company’s property is not the subject of any pending legal proceedings.

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29